Core Framework & Diagram Future Directions in Tumor Immunology

Access is rapidly improving. Multiple immune checkpoint inhibitors are now approved in China; domestic-developed PD-1/PD-L1 inhibitors (from Innovent, BeiGene, Junshi) are in clinical use. For CAR-T, China has multiple approved commercial products. For personalized neoantigen vaccines, multiple research institutions in China have clinical trials ongoing. For patients currently in treatment, asking your physician about suitable clinical trials is an important way to access the latest therapies.

This is one of the most important technical challenges in current tumor immunology. State-of-the-art AI prediction models (like MHCflurry 2.0, NetMHCpan 4.1) in predicting antigen-MHC I binding affinity have reached considerable precision (AUC exceeding 0.95 on known datasets). But from 'predicting MHC binding affinity' to 'predicting whether this neoantigen can actually be recognized by T cells and trigger effective immune response' there remains significant prediction error — approximately seventy to eighty percent of 'computationally predicted immunogenic neoantigens' don't actually induce effective T cell responses in actual testing. This is the core reason for still limited efficiency in the 'neoantigen selection' step of personalized tumor vaccine design.

This question is essentially the final message these fifteen articles (66–80) want to convey: maintaining immune system health is the most valuable long-term investment you can make today. Specifically: regular moderate-to-high intensity aerobic exercise (elevates NK cell and T cell function, improves tumor surveillance efficiency); sleep optimization (maintains cortisol rhythm, protects NK cell function window); managing chronic inflammation sources (screen for H. pylori, viral hepatitis, treat periodontal disease, control weight); reducing chronic stress; and standardized cancer screening (finding and intervening in the equilibrium phase, not waiting for escape phase).

Wide-scale availability may take ten to fifteen years. Main barriers are cost and preparation time: each personalized mRNA vaccine currently takes four to eight weeks to prepare at considerable cost. With continuously falling sequencing costs and mRNA manufacturing platform scale-up, and AI-assisted design greatly compressing preparation time, optimistically: within five to seven years, personalized vaccines may become standard adjuvant treatment for specific high-risk/relapsing cancers; within ten to fifteen years, expansion to broader cancer types and toward cancer prevention (high-risk populations) is expected.

From a cancer prevention perspective, treatment is recommended. H. pylori is a definitive Group 1 carcinogen (WHO classification), continuously pushing toward gastric cancer through the chronic gastritis → atrophic gastritis → intestinal metaplasia → gastric cancer progression. Taiwan Matsu's large-scale screening and eradication project showed gastric cancer incidence decreased over fifty percent after fifteen years. Standard triple or quadruple eradication therapy (approximately ten to fourteen days antibiotics + proton pump inhibitor) has over eighty percent efficacy with mild side effects. The earlier the eradication — before irreversible gastric mucosal damage — the better the preventive effect. For Asian populations (including Malaysia, Singapore, China, Taiwan) with higher H. pylori infection rates (some regions over fifty percent in adults), active screening and eradication is one of the most evidence-based and clearly beneficial gastric cancer prevention measures.